| Literature DB >> 19331414 |
Andrew J S Knox1, Trevor Price, Michal Pawlak, Georgia Golfis, Christopher T Flood, Darren Fayne, D Clive Williams, Mary J Meegan, David G Lloyd.
Abstract
We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compound. Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity. Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a commercial screening collection of 160 000 compounds.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19331414 DOI: 10.1021/jm801569z
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446